Physician profile
Robert C Sorenson
NPI 1366422917
$5,228.77
in general payments reported to CMS, 2019-2025
22 companies · $612 in 2025
The $612 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $1,701 · 2021: $166 · 2022: $115 · 2023: $103 · 2024: $1,301 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181 · Travel and Lodging: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.37 |
| Travel and Lodging | $834.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,967.07 | 2019-2025 | Idosetr, Istent Infinite |
| Alcon Vision LLC | $1,686.46 | 2019-2025 | Clareon, Rocklatan |
| Eyepoint US, INC. | $924.04 | 2019-2022 | |
| Rxsight INC | $102.70 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| New World Medical,INC. | $66.17 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $64.32 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $56.07 | 2019 | |
| Amgen INC. | $49.72 | 2024 | Tepezza |
| Shire North American Group INC | $42.73 | 2019 | |
| Allergan, INC. | $42.12 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $39.48 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $29.14 | 2020 | |
| Ivantis, INC | $27.60 | 2021 | |
| Kala Pharmaceuticals, INC. | $24.57 | 2019 | |
| Bausch & Lomb Americas INC. | $22.30 | 2025 | Stellaris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $19.73 | 2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $18.88 | 2022 | |
| Harrow Eye, LLC | $18.52 | 2024 | Vevye |
| Abbvie INC. | $14.42 | 2019 | |
| Horizon Therapeutics Plc | $12.73 | 2023 | Tepezza |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sorenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.